Home » Topics » BioWorld Science

BioWorld Science
RSS

Gossamer Bio presents DGKA and/or DGKZ inhibitors

Jan. 10, 2022

The Vanderbilt University divulges new muscarinic M5 receptor antagonists

Jan. 10, 2022

Dana-Farber Cancer Institute patents UCP1 activators

Jan. 10, 2022

Tucatinib plus anti-HER2 antibody NSCs prolong survival of mice with brain-metastatic breast cancer

Jan. 10, 2022

Researchers publish data on DDR kinase inhibitor XBLJ-13 for pulmonary fibrosis

Jan. 10, 2022

Novel roe-inspired MSC microcapsules for the treatment of IBD

Jan. 10, 2022

Indirect radiolabeling of pGlu for intratumoral delivery of alpha- and beta-particle emitters

Jan. 10, 2022

Identification of novel drug candidates targeting dengue virus capsid protein

Jan. 10, 2022

Down syndrome linked to senescence-like state

Jan. 10, 2022

Unity Biotechnology eyes IND-enabling studies with pipeline programs in 2022

Jan. 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...